Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
The team evaluated various technologies in an attempt to develop a framework to compare future methods against and to serve as a guide for researchers.
Some of the mutational signatures the researchers observed were similar to ones previously seen in B cell tumors, underscoring the link between aging and cancer.
The effort, outlined in a Development Cell paper published online today, aims to complement the ongoing Human Cell Atlas initiative, but with a focus on pediatric health.
The startup's technology, which it plans to launch through an early-access program this summer, is based on a cell fixing and combinatorial barcoding strategy.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
